AbbVie
ABBV
$144.60
Share price
2.03%
Change (1 day)
34.71%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Market capitalization of AbbVie (ABBV)
Market cap: $255.66 Billion
As of September 2022 AbbVie has a market cap of $255.66 Billion. This makes AbbVie the world's 27th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of AbbVie from 2012 to 2022
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2022 | $255.66 B | 6.81% |
| 2021 | $239.37 B | 26.54% |
| 2020 | $189.17 B | 44.47% |
| 2019 | $130.94 B | -3.95% |
| 2018 | $136.33 B | -11.7% |
| 2017 | $154.39 B | 51.71% |
| 2016 | $101.76 B | 6.7% |
| 2015 | $95.37 B | -8.42% |
| 2014 | $104.14 B | 24.23% |
| 2013 | $83.82 B | 55.32% |
| 2012 | $53.97 B |
End of Day market cap according to different sources
On Sep 28th, 2022 the market cap of AbbVie was reported to be:
$255.66 Billion
$255.66 Billion
$255.59 Billion
$255.66 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $249.35 B | -2.47% | 🇺🇸 USA |
 Eli Lilly LLY | $317.71 B | 24.27% | 🇺🇸 USA |
 Amgen AMGN | $123.55 B | -51.67% | 🇺🇸 USA |
 Biogen BIIB | $40.13 B | -84.30% | 🇺🇸 USA |
 Gilead Sciences GILD | $80.12 B | -68.66% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $153.86 B | -39.82% | 🇺🇸 USA |
 Astrazeneca AZN | $180.30 B | -29.48% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $59.52 B | -76.72% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $9.83 B | -96.15% | 🇺🇸 USA |